Basilea Pharmaceutica secured $39 million from the U.S. Biomedical Advanced Research and Development Authority (BARDA) as part of a potential $268 million long-term contract to develop novel antifungals. This funding tranche will support late-stage clinical trials of fosmanogepix for yeast infections and BAL2062 for mold infections, targeting life-threatening fungal diseases prevalent in immunocompromised patients. Basilea has a history of BARDA partnerships and markets other anti-infectives, advancing innovative compounds originating from Amplyx Pharmaceuticals and Gravitas Therapeutics.